Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-20T04:57:20.869Z Has data issue: false hasContentIssue false
  • English
  • Français

A Pilot Study of Plasma Thioridazine and Metabolites in Chronically Treated Patients

Published online by Cambridge University Press:  29 January 2018

A. S. Papadopoulos ,
T. G. Chand ,
J. L. Crammer  and
S. Lader
A. S. Papadopoulos
Affiliation:
Institute of Psychiatry, London, S.E.5
T. G. Chand
Affiliation:
Cane Hill Hospital, Coulsdon, Surrey
J. L. Crammer
Affiliation:
Institute of Psychiatry, London, S.E.5
S. Lader
Affiliation:
Wellcome Research Laboratories, Beckenham, Kent
Get access Rights & Permissions [Opens in a new window]

Summary

Plasma concentrations of thioridazine, mesoridazine, sulphoridazine and thioridazine ring sulphoxide have been measured individually by specific gas-liquid chromatographic (GLC) methods, and collectively by a radio-receptor assay, in 16 elderly in-patients during chronic treatment. The sulphoridazine level was above 0.135 μg/ml in 5 out of 6 symptomatically well-controlled patients, and below this level in 9 out of 10 who were poorly controlled. No such division was so clear for the other substances measured. A new assay for the total dopamine receptor-blocking activity of the plasma correlated highly at lower levels with the sum of drug plus metabolites obtained by GLC, but exceeded the sum at higher values. Both sulphoridazine and neuroleptic levels need further study.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 136 , Issue 6 , June 1980 , pp. 591 - 596
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Axelsson, R. (1977) On the serum concentration and antipsychotic effects of thioridazine, thioridazine side-chain sulphoxide and thioridazine side-chain sulphone in chronic psychotic patients. Current Therapeutic Research, 20, 587–605.Google Scholar
Axelsson, R. & Mårtensson, E. (1977) The concentration pattern of non-conjugated thioridazine metabolites in serum in thioridazine treatment and its relationship to physiological and clinical variables. Current Therapeutic Research, 20, 561–86.Google Scholar
Axelsson, R. & Mårtensson, E. (1978) Relationship between serum concentrations of thioridazine and its main non-conjugated metabolites and the clinical response in thioridazinetreated patients. Current Therapeutic Research, 24, 232–42.Google Scholar
Gruenke, L. D., Craig, J. C., Dinovo, E. C., Gottschalk, L. A., Noble, E. P. & Biener, R. (1975) Identification of a metabolite of thioridazine and mesoridazine from human plasma. Research Communications in Chemical Pathology and Pharmacology, 10, 221–5.Google Scholar
Lader, S. (1980) A radioreceptor assay for neuroleptic drugs in plasma. Journal of Immunoassay, 1, 57–75.CrossRefGoogle ScholarPubMed
Mackay, A. V. P., Healey, A. F. & Baker, J. (1974) The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. British Journal of Clinical Pharmacology, 1, 425–30.CrossRefGoogle Scholar
Mårtensson, E., Nyberg, G. & Axelsson, R. (1975) Quantitative determination of thioridazine and non-conjugated thioridazine metabolites in serum and urine of psychiatric patients. Current Therapeutic Research, 18, 687–700.Google Scholar
No, C. H. & Crammer, J. L. (1977) Measurement of thioridazine in blood and urine. British Journal of Clinical Pharmacology, 4, 173–83.Google Scholar
Nyberg, G., Axelsson, R. & Mårtensson, E. (1978) Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. European Journal of Clinical Pharmacology, 14, 341–50.Google Scholar
Simpson, G. M. & Angus, J. W. (1970) Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica, Suppl. 212, p. 11.Google Scholar
Traficante, L. J., Siekierski, J. & Gershon, S. (1979) Sulfoxidation of chlorpromazine and thioridazine by bovine liver-preferential metabolic pathways. Biochemical Pharmacology, 28, 621–6.CrossRefGoogle ScholarPubMed
Vanderheeren, F. A. J., Theunis, D. J. C. & Rosseel, M. T. (1976) Gas-liquid chromatographic determination of perazine, thioridazine and thioridazine metabolites in human plasma. Journal of Chromatography, 120, 123–8.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.